Argenx
Clinical trials sponsored by Argenx, explained in plain language.
-
Promising POTS drug study halted early – what we know
Disease control TerminatedThis study looked at the long-term safety of a drug called efgartigimod for adults with post-COVID POTS, a condition that causes rapid heart rate and dizziness when standing. It was an open-label extension, meaning everyone knew they were getting the drug. The study was terminate…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 06:01 UTC
-
Thyroid eye disease drug trial halted early – no safety issues
Disease control TerminatedThis study tested a drug called efgartigimod for adults with active, moderate-to-severe thyroid eye disease. Participants received either the drug or a placebo by injection. The trial was stopped early because early results showed the drug was unlikely to work as hoped, but no sa…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 05:57 UTC
-
Thyroid eye disease drug trial halted after disappointing results
Disease control TerminatedThis study tested a drug called efgartigimod for adults with active, moderate-to-severe thyroid eye disease, a condition that causes bulging eyes and vision problems. About 102 people were enrolled to receive either the drug or a placebo. The trial was stopped early because early…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 05:47 UTC
-
New drug shows promise for blistering skin disease, but Long-Term use needed
Disease control TerminatedThis study looked at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who completed an earlier study could receive the drug for up to 48 weeks, with the option to pause…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:02 UTC